Literature DB >> 19764700

Large-scale identification and quantification of covalent modifications in therapeutic proteins.

Zhongqi Zhang1.   

Abstract

Covalent modifications on therapeutic proteins are traditionally monitored by chromatographic techniques, which quantify limited number of protein modifications at a time. In this report, computer algorithms for automated analyses of liquid chromatography/tandem mass spectrometry (LC/MS/MS) data for large-scale identification and quantification of known and unknown modifications are described. Peptide identification is achieved by comparing the experimental fragmentation spectrum to the predicted spectrum of each native or modified peptide. Peak areas of related peptide ions under their selected-ion chromatograms (SIC) are used for relative quantification of modified peptides. A matched window function is used to generate SIC for more reliable quantification. In an LC/MS/MS analysis of a tryptic digestion of an IgG2 monoclonal antibody, 1712 peptide ions were identified with a false-discovery rate of approximately 0.4%, and 227 modifications were identified and quantified. The accuracy of the mass spectrometry-based quantification is evaluated by comparing the abundance of different glycoforms determined by mass spectrometry to that determined by a fluorescence-based chromatography method. This large-scale method may potentially replace many chromatographic methods for assessing the quality attributes of therapeutic proteins.

Mesh:

Substances:

Year:  2009        PMID: 19764700     DOI: 10.1021/ac901193n

Source DB:  PubMed          Journal:  Anal Chem        ISSN: 0003-2700            Impact factor:   6.986


  29 in total

1.  Retention time alignment of LC/MS data by a divide-and-conquer algorithm.

Authors:  Zhongqi Zhang
Journal:  J Am Soc Mass Spectrom       Date:  2012-04       Impact factor: 3.109

2.  Automated precursor ion exclusion during LC-MS/MS data acquisition for optimal ion identification.

Authors:  Zhongqi Zhang
Journal:  J Am Soc Mass Spectrom       Date:  2012-06-06       Impact factor: 3.109

3.  Discovery and characterization of hydroxylysine in recombinant monoclonal antibodies.

Authors:  Qing Xie; Benjamin Moore; Richard L Beardsley
Journal:  MAbs       Date:  2015-12-14       Impact factor: 5.857

4.  Molecular basis for the loss-of-function effects of the Alzheimer's disease-associated R47H variant of the immune receptor TREM2.

Authors:  Athena Sudom; Santosh Talreja; Jean Danao; Eric Bragg; Rob Kegel; Xiaoshan Min; Jason Richardson; Zhongqi Zhang; Nikolai Sharkov; Edoardo Marcora; Steve Thibault; Jodi Bradley; Steve Wood; Ai-Ching Lim; Hang Chen; Songli Wang; Ian N Foltz; Shilpa Sambashivan; Zhulun Wang
Journal:  J Biol Chem       Date:  2018-05-24       Impact factor: 5.157

5.  Elucidation of degradants in acidic peak of cation exchange chromatography in an IgG1 monoclonal antibody formed on long-term storage in a liquid formulation.

Authors:  Sejal Gandhi; Da Ren; Gang Xiao; Pavel Bondarenko; Christopher Sloey; Margaret Speed Ricci; Sampathkumar Krishnan
Journal:  Pharm Res       Date:  2011-08-16       Impact factor: 4.200

6.  Rapid identification of an antibody DNA construct rearrangement sequence variant by mass spectrometry.

Authors:  Rebecca A Scott; Rich Rogers; Alain Balland; Lowell J Brady
Journal:  MAbs       Date:  2014       Impact factor: 5.857

7.  Development of a quantitative mass spectrometry multi-attribute method for characterization, quality control testing and disposition of biologics.

Authors:  Richard S Rogers; Nancy S Nightlinger; Brittney Livingston; Phil Campbell; Robert Bailey; Alain Balland
Journal:  MAbs       Date:  2015-07-17       Impact factor: 5.857

8.  Expression vector-derived heterogeneity in a therapeutic IgG4 monoclonal antibody.

Authors:  Douglas S Rehder; Chris J Wisniewski; Denfeng Liu; Diya Ren; Dell Farnan; Matthew R Schenauer
Journal:  MAbs       Date:  2018-11-07       Impact factor: 5.857

9.  Discovery, characterization, and remediation of a C-terminal Fc-extension in proteins expressed in CHO cells.

Authors:  Christopher S Spahr; Mark E Daris; Kevin C Graham; Brian D Soriano; Jennitte L Stevens; Stone D-H Shi
Journal:  MAbs       Date:  2018-09-20       Impact factor: 5.857

Review 10.  Assessing monoclonal antibody product quality attribute criticality through clinical studies.

Authors:  Andrew M Goetze; Matthew R Schenauer; Gregory C Flynn
Journal:  MAbs       Date:  2010-09-01       Impact factor: 5.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.